We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Bio-Innovation Agreement to Strengthen Ties between Canada and Israel

By LabMedica International staff writers
Posted on 31 May 2016
Print article
A recently signed agreement aims at encouraging academic and entrepreneurial ties in the field of bio-innovation between a Canadian and an Israeli university.

The agreement will establish a strong relationship between the University of Toronto (Canada) – in the form of the Institute of Biomaterials and Biomedical Engineering – and The Hebrew University of Jerusalem (Israel) – in the form of the Alexander Grass Center for Bioengineering.

The agreement, which is called the Jerusalem-Toronto Bio-Innovation Partnership, will strengthen the exchange of students, faculty, and ideas between the academic and entrepreneurial environments of the two universities. In addition, it will provide financial support for students in engineering, biology, and computer science to conduct research in the partner country over a 12-week period.

An intensive eight-week educational program – the Transdisciplinary Innovation Program – that weaves together computer vision, big data, and bioengineering will also be offered to students from the University of Toronto, enabling interaction with Nobel laureates, work under the mentorship of Israeli scientists and entrepreneurs, and the opportunity for students to pitch ideas to investors.

Faculty and student groups will travel between the two countries to advance the collaboration, and a joint BioDesign program will bring together engineers, clinicians, and business and engineering students to share and create knowledge with tangible impact.

Dr. Meric Gertler, president of the University of Toronto, said, “The forthcoming projects with The Hebrew University of Jerusalem are important to the University of Toronto. They underscore a commitment on the part of both universities to harness the power of Israel’s and Canada’s brightest minds to find solutions to the world's pressing social and medical problems. They will provide exciting opportunities in the near-term and, I believe, stand to have meaningful long-run impact by virtue of the skills investment and advances they entail.”

Dr. Menahem Ben-Sasson, president of The Hebrew University of Jerusalem, said, “The Hebrew University is very pleased to expand its partnership with the University of Toronto. This agreement will bring about new exchanges of people and ideas between two of the world’s leading centers of research and academia. Furthermore it will drive cooperation in medical, social and entrepreneurial studies and research that will benefit Canada, Israel and the entire world.”

Related Links:
University of Toronto
The Hebrew University of Jerusalem

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.